
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
For Contemporary Pediatrics, Dr Bobby Lazzara explains key findings from a study published in Pediatrics. The study looked at whether children and adolescents who engage in nonmedical use of opioid medications are increasing their future risk of heroin use.
For Contemporary Pediatrics, Dr Bobby Lazzara explains key findings from a study published in Pediatrics. The study looked at whether children and adolescents who engage in nonmedical use of opioid medications are increasing their future risk of heroin use.






